Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Acute Non-Lymphocytic Leukemias

Absolute lymphocyte count recovery after induction chemotherapy predicts superior survival in acute myelogenous leukemia

Abstract

Absolute lymphocyte count (ALC) recovery postautologous stem cell transplantation is an independent predictor for survival in acute myelogenous leukemia (AML). The role of ALC recovery after induction chemotherapy (IC) in AML is unknown. We hypothesize that ALC recovery after IC has a direct impact on survival. We have now evaluated the impact of ALC recovery after IC on overall survival (OS) and leukemia-free survival (LFS) in 103 consecutive, newly diagnosed AML patients treated with standard IC and consolidation chemotherapy (CC) from 1998 to 2002. ALC recovery was studied at days 15 (ALC-15), 21 (ALC-21), 28 (ALC-28) after IC and before the first CC (ALC-CC). Superior OS and LFS at each time point were observed with an ALC-15, ALC-21, ALC-28, and ALC-CC 500 cells/μl. Patients with an ALC 500 cells/μl at all time points vs those who did not have superior OS and LFS (not reached vs 13 months, P<0.0001; and not reached vs 11 months, P<0.0001, respectively). Multivariate analysis demonstrated ALC 500 cells/μl at all time points to be an independent prognostic factor for survival. Our data suggest a critical role of lymphocyte (immune) recovery on survival after IC in AML.

This is a preview of subscription content, access via your institution

Access options

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2

Similar content being viewed by others

References

  1. Porrata LF, Litzow MR, Tefferi A, Letendre L, Kumar S, Geyer SM et al. Early lymphocyte recovery is a predictive factor for prolonged survival after autologous hematopoietic stem cell transplantation for acute myelogenous leukemia. Leukemia 2002; 16: 1311–1318.

    Article  CAS  Google Scholar 

  2. Porrata LF, Gertz MA, Inwards DJ, Litzow MR, Lacy MQ, Tefferi A et al. Early lymphocyte recovery predicts superior survival after autologous hematopoietic stem cell transplantation in multiple myeloma or non-Hodgkin lymphoma. Blood 2001; 98: 579–585.

    Article  CAS  Google Scholar 

  3. Porrata LF, Inwards DJ, Micallef IN, Ansell SM, Geyer SM, Markovic SN . Early lymphocyte recovery post-autologous haematopoietic stem cell transplantation is associated with better survival in Hodgkin's disease. Br J Haematol 2002; 117: 629–633.

    Article  Google Scholar 

  4. Porrata LF, Ingle JN, Litzow MR, Geyer S, Markovic SN . Prolonged survival associated with early lymphocyte recovery after autologous hematopoietic stem cell transplantation for patients with metastatic breast cancer. Bone Marrow Transplantation 2001; 28: 865–871.

    Article  CAS  Google Scholar 

  5. Porrata LF, Gertz MA, Litzow MR, Lacy MQ, Dispenzieri A, Inwards DJ et al. Early lymphocyte recovery predicts superior survival after autologous hematopoietic stem cell transplantation for patients with primary systemic amyloidosis. Clin Cancer Res 2005; 11: 1210–1218.

    CAS  PubMed  Google Scholar 

  6. Kaplan EL, Meier P . Non parametric estimates from incomplete observations. J Am Stat Assoc 1958; 53: 457–481.

    Article  Google Scholar 

  7. Faderl S, Thall PF, Kantarjian HM, Estrov Z . Time to platelet recovery predicts outcome of patients with de novo acute lymphoblastic leukaemia who have achieved a complete remission. Br J Haematol 2002; 117: 869–874.

    Article  Google Scholar 

  8. Mackall CL, Fleisher TA, Brown MR, Magrath IT, Shad AT, Horowitz ME et al. Lymphocyte depletion during treatment with intensive chemotherapy for cancer. Blood 1994; 84: 2221–2228.

    CAS  Google Scholar 

  9. Lowdell MW, Craston R, Samuel D, Wood ME, O'Neill E, Saha V et al. Evidence that continued remission in patients treated for acute leukaemia is dependent upon autologous natural killer cells. Br J Haematol 2002; 117: 821–827.

    Article  CAS  Google Scholar 

  10. Lotzova E . Definition and functions of natural killer cells. Nat Immun 1993; 12: 169–176.

    CAS  PubMed  Google Scholar 

  11. Pross HF, Lotzova E . Role of natural killer cells in cancer. Nat Immun 1993; 12: 279–292.

    CAS  PubMed  Google Scholar 

  12. Lotzova E, Savary CA . Human natural killer cell development from bone marrow progenitors: analysis of phenotype, cytotoxicity and growth. Nat Immun 1993; 12: 209–217.

    CAS  PubMed  Google Scholar 

  13. Lotzova E, Savary CA, Champlin RE . Genesis of human oncolytic natural killer cells from primitive CD34+CD33− bone marrow progenitors. J Immunol 1993; 150: 5263–5269.

    CAS  PubMed  Google Scholar 

  14. Tomblyn MR, Tallman MS . New developments in antibody therapy for acute myeloid leukemia. Semin Oncology 2003; 30: 502–508.

    Article  CAS  Google Scholar 

  15. Dunussi-Joannopoulos K, Runyon K, Erickson J, Schaub RG, Hawley RG, Leonard JP . Vaccines with interleukin-12 transduced acute myeloid leukemia cells elicit very potent therapeutic and long-lasting protective immunity. Blood 1999; 94: 4263–4273.

    CAS  Google Scholar 

  16. Fujii S, Fujimoto K, Shimizu K, Ezaki T, Fumio K, Takatsuki K et al. Presentation of tumor antigens by phagocytic dendritic cell clusters generated from human CD43 (+) hematopoietic progenitor cells; induction of autologous cytotoxic T-lymphocytes against leukemic cells in acute myelogenous leukemia patients. Cancer Res 1999; 59: 2150–2158.

    CAS  PubMed  Google Scholar 

  17. Kaufmann SH, Steensma DP . On the TRAIL of a new therapy for leukemia. Leukemia 2005, (Advanced online publication, 13 October, 2005).

Download references

Author information

Authors and Affiliations

Authors

Corresponding authors

Correspondence to L F Porrata or M R Litzow.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Behl, D., Porrata, L., Markovic, S. et al. Absolute lymphocyte count recovery after induction chemotherapy predicts superior survival in acute myelogenous leukemia. Leukemia 20, 29–34 (2006). https://doi.org/10.1038/sj.leu.2404032

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.leu.2404032

Keywords

This article is cited by

Search

Quick links